Hypertension, antihypertensive therapy and renal-cell cancer

A meta-analysis

Giovanni Corrao, Lorenza Scotti, Vincenzo Bagnardi, Roberto Sega

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The relationship between hypertension, antihypertensive treatments and the risk of renal-cell cancer (RCC) remains still controversial. To evaluate the strength of the evidence provided by the epidemiological literature on this topic, a MEDLINE search of the papers published from 1966 to 2006 was performed. A total of 18 studies were included in the analysis. Pooled estimates of the effects of interest were obtained by fitting random effect models to the original data. The effects of some characteristics of the studies were considered as putative sources of heterogeneity of the estimates. Significant increased risks of RCC associated with hypertension (pooled odds ratio 1.62; 95% confidence interval: 1.24 to 2.12), as well as with the use of both diuretics (1.43; 1.12 to 1.83) and no diuretics (1.51; 1.21 to 1.87) antihypertensive drugs were observed. The effect of diuretics was significant in women (1.92; 1.59 to 2.33), but not in men (1.18; 0.93 to 1.49). Allowance for the known risk factors of RCC appreciably modified the effect of no diuretic antiltypertensives making its pooled estimate not significant (1.17; 0.94 to 1.46). Although the pooled estimates show that both, hypertension and hypertensive therapy, are statistically associated with increased risk of RCC, experimental data and a closer look on the original data from epidemiologic literature, show that available evidence are still uncertain and need to be further investigated.

Original languageEnglish
Pages (from-to)125-133
Number of pages9
JournalCurrent Drug Safety
Volume2
Issue number2
DOIs
Publication statusPublished - May 2007

Fingerprint

Renal Cell Carcinoma
Diuretics
Antihypertensive Agents
Meta-Analysis
Hypertension
Therapeutics
MEDLINE
Odds Ratio
Confidence Intervals

Keywords

  • Antihypertensive medicaments
  • Hypertension
  • Meta-analysis
  • Renal-cell cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Toxicology
  • Pharmacology

Cite this

Hypertension, antihypertensive therapy and renal-cell cancer : A meta-analysis. / Corrao, Giovanni; Scotti, Lorenza; Bagnardi, Vincenzo; Sega, Roberto.

In: Current Drug Safety, Vol. 2, No. 2, 05.2007, p. 125-133.

Research output: Contribution to journalArticle

Corrao, Giovanni ; Scotti, Lorenza ; Bagnardi, Vincenzo ; Sega, Roberto. / Hypertension, antihypertensive therapy and renal-cell cancer : A meta-analysis. In: Current Drug Safety. 2007 ; Vol. 2, No. 2. pp. 125-133.
@article{40cf00cd079d4784ad4480037ec36035,
title = "Hypertension, antihypertensive therapy and renal-cell cancer: A meta-analysis",
abstract = "The relationship between hypertension, antihypertensive treatments and the risk of renal-cell cancer (RCC) remains still controversial. To evaluate the strength of the evidence provided by the epidemiological literature on this topic, a MEDLINE search of the papers published from 1966 to 2006 was performed. A total of 18 studies were included in the analysis. Pooled estimates of the effects of interest were obtained by fitting random effect models to the original data. The effects of some characteristics of the studies were considered as putative sources of heterogeneity of the estimates. Significant increased risks of RCC associated with hypertension (pooled odds ratio 1.62; 95{\%} confidence interval: 1.24 to 2.12), as well as with the use of both diuretics (1.43; 1.12 to 1.83) and no diuretics (1.51; 1.21 to 1.87) antihypertensive drugs were observed. The effect of diuretics was significant in women (1.92; 1.59 to 2.33), but not in men (1.18; 0.93 to 1.49). Allowance for the known risk factors of RCC appreciably modified the effect of no diuretic antiltypertensives making its pooled estimate not significant (1.17; 0.94 to 1.46). Although the pooled estimates show that both, hypertension and hypertensive therapy, are statistically associated with increased risk of RCC, experimental data and a closer look on the original data from epidemiologic literature, show that available evidence are still uncertain and need to be further investigated.",
keywords = "Antihypertensive medicaments, Hypertension, Meta-analysis, Renal-cell cancer",
author = "Giovanni Corrao and Lorenza Scotti and Vincenzo Bagnardi and Roberto Sega",
year = "2007",
month = "5",
doi = "10.2174/157488607780598296",
language = "English",
volume = "2",
pages = "125--133",
journal = "Current Drug Safety",
issn = "1574-8863",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Hypertension, antihypertensive therapy and renal-cell cancer

T2 - A meta-analysis

AU - Corrao, Giovanni

AU - Scotti, Lorenza

AU - Bagnardi, Vincenzo

AU - Sega, Roberto

PY - 2007/5

Y1 - 2007/5

N2 - The relationship between hypertension, antihypertensive treatments and the risk of renal-cell cancer (RCC) remains still controversial. To evaluate the strength of the evidence provided by the epidemiological literature on this topic, a MEDLINE search of the papers published from 1966 to 2006 was performed. A total of 18 studies were included in the analysis. Pooled estimates of the effects of interest were obtained by fitting random effect models to the original data. The effects of some characteristics of the studies were considered as putative sources of heterogeneity of the estimates. Significant increased risks of RCC associated with hypertension (pooled odds ratio 1.62; 95% confidence interval: 1.24 to 2.12), as well as with the use of both diuretics (1.43; 1.12 to 1.83) and no diuretics (1.51; 1.21 to 1.87) antihypertensive drugs were observed. The effect of diuretics was significant in women (1.92; 1.59 to 2.33), but not in men (1.18; 0.93 to 1.49). Allowance for the known risk factors of RCC appreciably modified the effect of no diuretic antiltypertensives making its pooled estimate not significant (1.17; 0.94 to 1.46). Although the pooled estimates show that both, hypertension and hypertensive therapy, are statistically associated with increased risk of RCC, experimental data and a closer look on the original data from epidemiologic literature, show that available evidence are still uncertain and need to be further investigated.

AB - The relationship between hypertension, antihypertensive treatments and the risk of renal-cell cancer (RCC) remains still controversial. To evaluate the strength of the evidence provided by the epidemiological literature on this topic, a MEDLINE search of the papers published from 1966 to 2006 was performed. A total of 18 studies were included in the analysis. Pooled estimates of the effects of interest were obtained by fitting random effect models to the original data. The effects of some characteristics of the studies were considered as putative sources of heterogeneity of the estimates. Significant increased risks of RCC associated with hypertension (pooled odds ratio 1.62; 95% confidence interval: 1.24 to 2.12), as well as with the use of both diuretics (1.43; 1.12 to 1.83) and no diuretics (1.51; 1.21 to 1.87) antihypertensive drugs were observed. The effect of diuretics was significant in women (1.92; 1.59 to 2.33), but not in men (1.18; 0.93 to 1.49). Allowance for the known risk factors of RCC appreciably modified the effect of no diuretic antiltypertensives making its pooled estimate not significant (1.17; 0.94 to 1.46). Although the pooled estimates show that both, hypertension and hypertensive therapy, are statistically associated with increased risk of RCC, experimental data and a closer look on the original data from epidemiologic literature, show that available evidence are still uncertain and need to be further investigated.

KW - Antihypertensive medicaments

KW - Hypertension

KW - Meta-analysis

KW - Renal-cell cancer

UR - http://www.scopus.com/inward/record.url?scp=34249284139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249284139&partnerID=8YFLogxK

U2 - 10.2174/157488607780598296

DO - 10.2174/157488607780598296

M3 - Article

VL - 2

SP - 125

EP - 133

JO - Current Drug Safety

JF - Current Drug Safety

SN - 1574-8863

IS - 2

ER -